BFM
SGMT icon

Boothbay Fund Management’s Sagimet Biosciences SGMT Stock Holding History

Boothbay Fund Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,518
Closed -$40.8K – 1734
2025
Q1 		$40.8K Hold
12,518
– – ﹤0.01% 1298
2024
Q4 		$56.3K Sell
12,518
-102,433
-89% -$519K ﹤0.01% 1343
2024
Q3 		$318K Sell
114,951
-7,414
-6% -$22.9K 0.01% 1195
2024
Q2 		$418K Hold
122,365
– – 0.01% 1050
2024
Q1 		$663K Buy
+122,365
New +$879K 0.01% 902

Other funds holding SGMT

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return

Boothbay Fund Management's SGMT Position: Q2 2025 in Review

Boothbay Fund Management sold out of Sagimet Biosciences (SGMT) in Q2 2025, closing a stake of 12,518 shares — an estimated $40.8K sold.

Boothbay Fund Management first reported a position in SGMT in Q1 2024 and held it in 5 quarters. The position peaked at $663K in Q1 2024. 67 funds tracked by Wall St. Rank hold SGMT as of Q2 2025.

  • Boothbay Fund Management reported no remaining Sagimet Biosciences position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 12,518 Sagimet Biosciences shares in Q2 2025, an estimated $40.8K.
  • Boothbay Fund Management first reported a position in Sagimet Biosciences in Q1 2024 and held it in 5 quarters.
  • Boothbay Fund Management's Sagimet Biosciences position peaked at $663K in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.